Results 31 to 40 of about 41,330 (277)

Clinical characteristics in immune thrombocytopenia patients after COVID-19 vaccination

Human Vaccines & Immunotherapeutics, 2022
It is well documented that COVID-19 vaccines greatly reduce the severity and complications of SARS-CoV-2 infection. However, it has been reported that COVID-19 related vaccines may induce or exacerbate autoimmune hematological disorders, for example, a ...
Yimei Feng, Yao Quan, Kaniel Cassady, Zhongmin Zou, Yuan Gao, Xi Zhang   +5 more
doaj   +1 more source

Identifying and Treating Refractory ITP: Difficulty in Diagnosis and Role of Combination Treatment.

Blood, 2019
Immune Thrombocytopenia (ITP) is the commonest acquired thrombocytopenia after chemotherapy-induced thrombocytopenia. Existing guidelines describe the management and treatment of most patients who overall do well, even if they present with chronic ...
Oriana Miltiadous, M. Hou, J. Bussel
semanticscholar   +1 more source

Use of Eltrombopag in Children With Chronic Immune Thrombocytopenia (ITP): A Real Life Retrospective Multicenter Experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP)

Frontiers in Medicine, 2020
Background: The thrombopoietin receptor agonist eltrombopag has been shown to be safe and effective for children with chronic immune thrombocytopenia (ITP).
P. Giordano, G. Lassandro, A. Barone, S. Cesaro, Ilaria Fotzi, F. Giona, S. Ladogana, M. Miano, A. Marzollo, M. Nardi, L. Notarangelo, A. Pession, A. Ruggiero, G. Russo, P. Saracco, M. Spinelli, Alessandra Tolva, A. Tornesello, Valentina Palladino, G. D. Del Vecchio   +19 more
semanticscholar   +1 more source

Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review

Platelets, 2021
Previous meta-analyses reported discordant results on the efficacy and safety of thrombopoietin receptor agonists (TPO-RA) as second-line treatment in patients with immune thrombocytopenia (ITP). We conducted a meta-analysis of primary ITP treatment with
Simone Birocchi, Gian Marco Podda, Marco Manzoni, Giovanni Casazza, Marco Cattaneo   +4 more
doaj   +1 more source

Immune Thrombocytopenia (ITP): Current Limitations in Patient Management

Medicina, 2020
Primary immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by isolated thrombocytopenia caused by increased platelet destruction and impaired platelet production.
Deirdra R. Terrell, C. Neunert, N. Cooper, K. Heitink-Polle, C. Kruse, P. Imbach, T. Kühne, W. Ghanima   +7 more
semanticscholar   +1 more source

TPO for ITP in pregnancy [PDF]

Blood, 2017
In this issue of Blood , Kong et al describe a novel approach to immune thrombocytopenia (ITP) in pregnancy ...
James B. Bussel, Eun-Ju Lee
openaire   +3 more sources

Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP)

Platelets, 2020
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder in which autoantibodies and/or autoreactive T cells destroy platelets and megakaryocytes in the spleen and bone marrow, respectively.
R. Kapur, Rukhsana Aslam, E. Speck, Johan Rebetz, J. Semple   +4 more
semanticscholar   +1 more source

Quantization and variational problem of the Gubser-Rocha Einstein-Maxwell-Dilaton model, conformal and non-conformal deformations, and its proper thermodynamics

Journal of High Energy Physics, 2023
We show that the strongly coupled field theory holographically dual to the Gubser-Rocha anti-de-Sitter Einstein-Maxwell-Dilaton theory describes not a single non-trivial AdS2 IR fixed point, but a one-parameter family.
Nicolas Chagnet, Floris Balm, Koenraad Schalm   +2 more
doaj   +1 more source

Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.

Blood, 2017
In phase 2/3 trials, eltrombopag treatment of 6 months or less in patients with chronic/persistent immune thrombocytopenia (ITP) increased platelet counts and reduced bleeding.
R. Wong, M. Saleh, A. Khelif, A. Salama, M. S. Portella, P. Burgess, J. Bussel   +6 more
semanticscholar   +1 more source

Cognitive Outcome After Deep Brain Stimulation for Refractory Obsessive–Compulsive Disorder: A Systematic Review

Neuromodulation: Technology at the Neural Interface, EarlyView., 2021
Abstract Introduction Deep brain stimulation (DBS) is an effective treatment for refractory obsessive–compulsive disorder (OCD). Neuropsychological assessment contributes to DBS treatment in several ways: it monitors the cognitive safety of the treatment, identifies beneficial or detrimental cognitive side effects and it could aid to explain ...
Tim A. M. Bouwens van der Vlis, Annelien Duits, Mégan M. G. H. van de Veerdonk, Anne E. P. Mulders, Koen R. J. Schruers, Yasin Temel, Linda Ackermans, Albert F. G. Leentjens   +7 more
wiley   +1 more source